TY - JOUR AU - Masago, Katsuhiro AU - Fujita, Shiro AU - Yatabe, Yasushi PY - 2018 TI - Targeting minimal residual disease after surgery with molecular targeted therapy: the real path to a cure? JF - Journal of Thoracic Disease; Vol 10, Supplement 17 (June 20, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Stage II–IIIA non-small cell lung cancer (NSCLC) affects a highly heterogeneous group of patients with differences in the extent and localization of the disease, and the definition of stage II–IIIA disease has changed over time. The 5-year survival for completely resected stage II–IIIA NSCLC patients is poor (36–60%) (1). Indeed, at least one-third of patients show recurrences after surgery. UR - https://jtd.amegroups.org/article/view/21118